<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E4599F86-E5D9-40AD-A427-4782E12EA8BF"><gtr:id>E4599F86-E5D9-40AD-A427-4782E12EA8BF</gtr:id><gtr:name>Swiss Federal Institute of Technology in Lausanne (EPFL)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3365522A-B8C4-48F1-9A44-6639D10D9E65"><gtr:id>3365522A-B8C4-48F1-9A44-6639D10D9E65</gtr:id><gtr:name>Bicycle Therapeutics</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AB7C0822-BBCB-4C61-85EC-5D13C7A31759"><gtr:id>AB7C0822-BBCB-4C61-85EC-5D13C7A31759</gtr:id><gtr:name>MRC Laboratory of Molecular Biology</gtr:name><gtr:address><gtr:line1>Hills Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 2QH</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AB7C0822-BBCB-4C61-85EC-5D13C7A31759"><gtr:id>AB7C0822-BBCB-4C61-85EC-5D13C7A31759</gtr:id><gtr:name>MRC Laboratory of Molecular Biology</gtr:name><gtr:address><gtr:line1>Hills Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 2QH</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E4599F86-E5D9-40AD-A427-4782E12EA8BF"><gtr:id>E4599F86-E5D9-40AD-A427-4782E12EA8BF</gtr:id><gtr:name>Swiss Federal Institute of Technology in Lausanne (EPFL)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3365522A-B8C4-48F1-9A44-6639D10D9E65"><gtr:id>3365522A-B8C4-48F1-9A44-6639D10D9E65</gtr:id><gtr:name>Bicycle Therapeutics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/DD5EEC6E-E775-44BA-9A34-9760150B2ECE"><gtr:id>DD5EEC6E-E775-44BA-9A34-9760150B2ECE</gtr:id><gtr:firstName>G</gtr:firstName><gtr:surname>Winter</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UP_A024_1105"><gtr:id>5EF7F13E-43F8-4AA1-850C-D88F5563E075</gtr:id><gtr:title>Chemistry of Bicycles</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UP_A024_1105</gtr:grantReference><gtr:abstractText>We are trying to develop the methods to make a new class of drugs. Most drugs are small molecules that are made by chemistry and are taken by mouth; others, like antibodies, are proteins (large folded polypeptides) that are made by biological methods and are injected. There are many systematic advantages and disadvantages of these two classes of drugs; in particular it is much easier to make antibodies than small molecule drugs, as biological methods (accelerated evolution) are much faster than chemical methods. However the polypeptides are easily digested (which is why they have to be injected); and they do not easily leave the blood stream or enter cells. We are trying to combine the advantages of these two classes of drugs by using simple chemistry with accelerated evolution, and have already produced small indigestible polypeptides against some pharmaceutical targets. However the work is still at an early stage; we do not yet know whether we can combine all the advantages of small molecules and antibodies. Nevertheless a combination of only some of the advantages could prove sufficient to make valuable drugs that are very difficult to make by existing methods; for example, drugs that enter cancer cells and precisely block the targets active in the cancer process.</gtr:abstractText><gtr:technicalSummary>Peptide libraries are a rich source of molecular diversity and potentially of powerful drugs. However, peptide drugs suffer from a number of systemic shortcomings inherent in peptide structure and chemistry. These include poor affinity for target due to conformational flexibility, poor serum stability and low bioavailability. Macrocycles are a class of powerful natural drugs and toxins derived from peptide backbones. Their structures reveal strategies (such as cyclization, chemical modification and cross-linking) that address the shortcomings of peptide drugs. However, in nature, macrocycles are produced through dedicated non-ribosomal synthesis pathways, which, so far, have proved refractory to engineering or evolution to produce tailor-made compounds. This research program is aimed at the synthesis and evolution of peptide macrocycles with therapeutic potential using ribosomal peptide synthesis and harnessing both natural and chemical combinatorial diversity for directed evolution of novel peptide macrocycles. In particular, the program is aimed at the phage display of diverse peptide libraries comprising a defined number of chemical functionalities that allow peptide cyclization and folding around one or multiple organic cores. By tethering discrete peptide loops to a chemical and rigid scaffold this strategy not only constrains conformational flexibility, and greatly reduces susceptibility to proteolytic degradation, but also extends the chemical diversity of peptides by virtue of the organic core, which may include a wide variety of functionalities not present in nature. Chemical diversity may be further expanded through the incorporation of unnatural amino acids in the peptide loops, specific chemical modification of side-chains and / or N- or C-termini. In combination with the power of repertoire selection, this approach promises to deliver tailor-made designer ligands of low molecular weight, defined compact structure and high serum stability with obvious potential as a novel class of bio-therapeutics.</gtr:technicalSummary><gtr:fund><gtr:end>2014-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>736986</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bicycle Therapeutics</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Developing therapies from bicyclic peptides</gtr:description><gtr:id>A5C5F35D-9027-4C32-9C2E-847C1720C46B</gtr:id><gtr:impact>Patent
Licensing agreement</gtr:impact><gtr:outcomeId>RNFG9DaV9TF-1</gtr:outcomeId><gtr:partnerContribution>Scientific researcher from Bicycle Therapeutics hosted by LMB to help develop technology</gtr:partnerContribution><gtr:piContribution>Provision of benchspace and access to equipment and comsumables to researcher; scientific guidance</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Swiss Federal Institute of Technology in Lausanne (EPFL)</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>EPFL Partnership</gtr:description><gtr:id>F00CE4F3-A6A1-400C-9298-F1596959AA64</gtr:id><gtr:impact>Licensing agreement</gtr:impact><gtr:outcomeId>BRTfrCt97Tg-1</gtr:outcomeId><gtr:partnerContribution>Prof Christian Heinis was scientific founder of Bicycles Therapeutics together with Greg Winter. Prof Heinis provided scientific advice and guidance.</gtr:partnerContribution><gtr:piContribution>My research team is working jointly with EPFL on the development of bicycles.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>LMB Royal Opening 2013</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E9041898-BEAD-40C1-9B4A-B8A9293A5A1E</gtr:id><gtr:impact>The Queen and HRH Prince Philip asked questions and expressed interest

Requests for visits</gtr:impact><gtr:outcomeId>5463964b520de6.18957136</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>117000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Medical Research Foundation</gtr:department><gtr:description>Jeantet Fellowship - Bernard</gtr:description><gtr:end>2013-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>2289000F-7B49-4F4D-961E-F4CF8C39130A</gtr:id><gtr:outcomeId>awRS39eG1Ce0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The invention relates to a method for altering the conformational diversity of a first repertoire of polypeptide ligands, comprising a plurality of polypeptides comprising at least two reactive groups separated by a loop sequence covalently linked to a molecular scaffold which forms covalent bonds with said reactive groups, to produce a second repertoire of polypeptide ligands, comprising assembling said second repertoire from the polypeptides and structural scaffold of said first repertoire, incorporating one of the following alterations: (a) altering at least one reactive group; or (b) altering the nature of the molecular scaffold; or (c) altering the bond between at least one reactive group and the molecular scaffold; or (d) any combination of (a), (b) or (c).</gtr:description><gtr:grantRef>MC_UP_A024_1105</gtr:grantRef><gtr:id>0BC09076-5C1A-421A-96CE-73F664CE0609</gtr:id><gtr:impact>Consolidation of IP state of Bicycle Therapeutics</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>sZxRAwekAWA</gtr:outcomeId><gtr:patentId>WO2011018227</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Peptide Libraries</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Bicycle Therapeutics</gtr:companyName><gtr:description>Bicycle Therapeutics is a biotechnology company developing a platform technology that enables the creation of a new generation of biotherapeutics which combine the desirable features of small molecules and biopharmaceuticals to create highly specific and highly stable drugs. 
http://www.bicycletherapeutics.com/</gtr:description><gtr:id>614C4592-D43B-4179-88D1-4502213FBE58</gtr:id><gtr:impact>Bicycles Therapeutics has entered into a collaboration and license agreement with ThromboG enics NV to develop potent and selective bicyclic peptide inhibitors against a specific drug target of interest for the treatment of ophthalmic diseases, such as diabetic macular edema (DME)</gtr:impact><gtr:outcomeId>VA4VbiFXPMG</gtr:outcomeId><gtr:url>http://www.bicycletherapeutics.com/</gtr:url><gtr:yearCompanyFormed>2009</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>33B45FDA-9B01-49CF-B9A0-61A373D9D02F</gtr:id><gtr:title>Backbone-driven collapse in unfolded protein chains.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56d3523d2f7264b44eb37e799be70d5e"><gtr:id>56d3523d2f7264b44eb37e799be70d5e</gtr:id><gtr:otherNames>Teufel DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>pm_15482_22_21497607</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5513C6A0-F3C5-4017-AD9C-E445430FC39C</gtr:id><gtr:title>Subunit disassembly and inhibition of TNFa by a semi-synthetic bicyclic peptide.</gtr:title><gtr:parentPublicationTitle>Protein engineering, design &amp; selection : PEDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/05592184934558eefb961d3ac4c3a79f"><gtr:id>05592184934558eefb961d3ac4c3a79f</gtr:id><gtr:otherNames>Luzi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1741-0126</gtr:issn><gtr:outcomeId>56e05d3fae9795.69962079</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>351FBC38-C36B-407D-BE0E-B9A03490A23A</gtr:id><gtr:title>Bicyclic peptides with optimized ring size inhibit human plasma kallikrein and its orthologues while sparing paralogous proteases.</gtr:title><gtr:parentPublicationTitle>ChemMedChem</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d359e4fc80d6c6f812208449b9f66dd5"><gtr:id>d359e4fc80d6c6f812208449b9f66dd5</gtr:id><gtr:otherNames>Baeriswyl V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1860-7179</gtr:issn><gtr:outcomeId>56e05d3fdaaef0.15808374</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DED607D7-72F2-4DBC-9F89-93C1D8CD7D54</gtr:id><gtr:title>Encoded libraries of chemically modified peptides.</gtr:title><gtr:parentPublicationTitle>Current opinion in chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33e60dc6b75273870ca983dfab206a64"><gtr:id>33e60dc6b75273870ca983dfab206a64</gtr:id><gtr:otherNames>Heinis C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1367-5931</gtr:issn><gtr:outcomeId>56e05dbf6209e4.06440589</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B12EEC5-49EE-4C5D-B818-936ACAE00F6A</gtr:id><gtr:title>CycloPs: generating virtual libraries of cyclized and constrained peptides including nonnatural amino acids.</gtr:title><gtr:parentPublicationTitle>Journal of chemical information and modeling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88d6a0ef40589314c9a5b2121cce1bd2"><gtr:id>88d6a0ef40589314c9a5b2121cce1bd2</gtr:id><gtr:otherNames>Duffy FJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1549-9596</gtr:issn><gtr:outcomeId>56e05e294aae38.80076750</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UP_A024_1105</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8EA3EC93-8E9C-482F-8121-C6C8413D9B6D</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.3  Chemical and physical sciences</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>